Enliven Therapeutics (NASDAQ:ELVN) CFO Benjamin Hohl Sells 10,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 10,000 shares of Enliven Therapeutics stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total value of $295,800.00. Following the completion of the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at $1,508,580. The trade was a 16.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Enliven Therapeutics Stock Performance

ELVN stock traded up $0.51 during trading on Tuesday, hitting $30.24. 965,304 shares of the company’s stock traded hands, compared to its average volume of 633,691. The business has a fifty day simple moving average of $25.88 and a two-hundred day simple moving average of $22.02. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.78.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently bought and sold shares of ELVN. Vestal Point Capital LP boosted its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in Enliven Therapeutics during the second quarter worth $9,990,000. Duquesne Family Office LLC raised its holdings in Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after buying an additional 484,405 shares during the period. Spruce Street Capital LP purchased a new position in shares of Enliven Therapeutics during the 4th quarter worth approximately $6,870,000. Finally, Polar Capital Holdings Plc raised its position in Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock valued at $54,111,000 after purchasing an additional 418,673 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ELVN has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $41.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.